Combined PET/CT imaging has become an integral part of patient management, particularly in oncology. After the imaging examination, a report of the findings is created by expert readers and sent to the referrers as a basis for subsequent decisions. In view of the known wide variation in operational models for PET/CT imaging, we surveyed PET/CT users on their approaches toward PET/CT reporting. The electronic survey comprised 28 questions on the demographics and professional background of the responders, as well as questions on the structure and quality of PET/CT reports, including the type of reported information, the use of reporting standards, and the mix of reporting standards and expert opinions. The survey was active for 6 wk in early 2018. In total, 242 responses were collected worldwide. The responders were mainly from Europe (78%), with 22% being nuclear medicine specialists, 42% radiologists, 22% dual board-certified, 10% residents in either nuclear medicine or radiology, and 5% medical physicists, radiographers, or oncologists. A slim majority (55%) of responses indicated reports being done according to the European Association of Nuclear Medicine 2015 guidelines for F-FDG PET/CT imaging, but 30% of responders were unaware of these guidelines. Report structures varied across sites, with most sites (38%) reporting the PET findings with supplementary localization information from CT, whereas 27% of sites reported along the lines of a CT report with supplementary PET information. One third of the sites included information on the TNM stage of the oncology patient in all reports, whereas 34% and 12% of sites included this information occasionally or only for selected tumors, respectively. For therapy response assessment, various well-established criteria were used. The number of sites utilizing these criteria ranged from 15% (European Organisation for Research and Treatment of Cancer criteria) to 57% (Deauville criteria). Broad variation in the PET/CT reporting strategies adopted for oncology studies and widespread lack of awareness of existing guidelines for PET/CT reporting are evident from responses to this survey, raising concerns as to whether reporting clinicians are optimally using the complementary information from each modality. Greater efforts are needed to ensure harmonization of reporting practices.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2967/jnumed.118.218073 | DOI Listing |
Ann Nucl Med
January 2025
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Objective: Using F-FDG PET/CT metabolic parameters to differentiate post-transplant lymphoproliferative disorder (PTLD) and reactive lymphoid hyperplasia (RLH), and PTLD subtypes.
Methods: F-FDG PET/CT and clinical data from 63 PTLD cases and 19 RLH cases were retrospectively collected. According to the 2017 WHO classification, PTLD was categorized into four subtypes: nondestructive (ND-PTLD), polymorphic (P-PTLD), monomorphic (M-PTLD), and classic Hodgkin.
Skeletal Radiol
January 2025
Department of Trauma, Hand and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Objective: This study is aimed at evaluating the distribution of metastatic bone disease (MBD), with a particular focus on the humerus, and its association with pathological fractures. Factors for contributing to the underestimation of fracture risk were assessed, including their impact on surgical management.
Materials And Methods: We retrospectively reviewed patient records of patients undergoing surgical treatment for MBD at our institution between 2005 and 2023.
Brain Imaging Behav
January 2025
Department of Medical Imaging, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Insomnia disorder is a significant global health concern. This research aimed to explore the pathogenesis of insomnia disorder using static and dynamic degree centrality methods at the voxel level. A total of 29 patients diagnosed with insomnia disorder and 28 healthy controls were ultimately included to examine differences in degree centrality between the two groups.
View Article and Find Full Text PDFClin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
J Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!